Share Price and Basic Stock Data
Last Updated: November 3, 2025, 8:04 pm
| PEG Ratio | 9.52 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Advanced Enzyme Technologies Ltd operates in the pharmaceuticals sector, specializing in enzyme manufacturing. The company reported a market capitalization of ₹3,451 Cr and a stock price of ₹308. Over recent quarters, revenue trends indicate a steady upward trajectory. Sales rose from ₹121 Cr in June 2022 to ₹158 Cr in September 2023, reflecting a compound quarterly growth rate of approximately 11.5%. For FY 2023, total sales stood at ₹541 Cr, a modest increase from ₹529 Cr in FY 2022. The latest reported data for FY 2025 indicates total sales are expected to reach ₹637 Cr, which suggests a sustained growth strategy. The operating profit margin (OPM) consistently remained robust, averaging around 30%, highlighting efficient cost management alongside revenue growth. The company’s commitment to innovation and expansion in enzyme applications is a likely driver of this growth, catering to diverse industries including pharmaceuticals, food, and biofuels.
Profitability and Efficiency Metrics
Advanced Enzyme Technologies Ltd’s profitability metrics exhibit a strong performance, with a net profit of ₹139 Cr reported for FY 2025. The net profit margin stood at 21.03%, which is above the typical pharmaceutical sector average, indicating effective operational efficiency. Additionally, the return on equity (ROE) was recorded at 9.54%, while the return on capital employed (ROCE) was at 13.1%, suggesting efficient utilization of both equity and capital. The interest coverage ratio (ICR) was exceptionally high at 63.95x, indicating that the company’s earnings comfortably cover its interest obligations. This financial strength reflects a conservative debt management approach, as borrowings were only ₹39 Cr, which translates to a debt-to-equity ratio of 0.01. However, the cash conversion cycle (CCC) of 403 days, while manageable, indicates room for improvement in working capital efficiency, particularly in inventory and receivables management.
Balance Sheet Strength and Financial Ratios
The balance sheet of Advanced Enzyme Technologies Ltd demonstrates a solid financial position, with total assets reported at ₹1,611 Cr as of March 2025. The company’s reserves increased to ₹1,398 Cr, showcasing a robust retention strategy. The equity capital has remained stable at ₹22 Cr, indicating a conservative approach to financing. The price-to-book value (P/BV) ratio stood at 2.20x, which is relatively low compared to industry standards, suggesting that the stock may be undervalued. Furthermore, with total borrowings at ₹39 Cr, the company’s low leverage enhances its financial stability. The current ratio of 9.09 indicates excellent liquidity, while the quick ratio of 7.47 further confirms the company’s ability to meet short-term obligations without relying on inventory sales. However, the declining trend in the operating profit margin from a high of 47.89% in FY 2021 to the latest 31% in FY 2025 requires monitoring.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Advanced Enzyme Technologies Ltd reflects a diversified ownership structure. As of March 2025, promoters held a stake of 43.08%, down from 49.88% in September 2022, indicating a gradual dilution of control. Foreign institutional investors (FIIs) reported a stake of 23.45%, which is a positive sign of international confidence in the company. Domestic institutional investors (DIIs) held 8.45%, while the general public accounted for 25% of the shares. This distribution suggests a healthy mix of institutional and retail investor interest. The number of shareholders increased to 67,589, indicating growing public interest. However, the declining promoter stake could raise concerns about long-term strategic direction. The company must ensure transparency and maintain investor confidence, especially as it navigates through changing ownership dynamics.
Outlook, Risks, and Final Insight
Looking ahead, Advanced Enzyme Technologies Ltd is poised for continued growth driven by its innovation in enzyme applications and expanding market reach. However, the company faces risks associated with potential fluctuations in raw material costs and regulatory changes in the pharmaceutical sector. Moreover, the high cash conversion cycle may affect liquidity if not addressed. While the company’s strong financial metrics and operational efficiency provide a robust foundation, maintaining profitability margins will be crucial. The company should focus on improving working capital management to enhance cash flow. If the current growth trajectory continues, and operational efficiencies are optimized, Advanced Enzyme Technologies Ltd could solidify its standing in the competitive pharmaceuticals market, potentially attracting more institutional investors and enhancing shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Advanced Enzyme Technologies Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 145 Cr. | 115 | 247/84.3 | 33.0 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 5,079 Cr. | 464 | 479/192 | 114 | 22.8 | 0.14 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 35.1 Cr. | 24.0 | 29.1/17.0 | 36.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,966.35 Cr | 1,197.73 | 54.46 | 195.30 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 139 | 142 | 139 | 147 | 158 | 161 | 158 | 155 | 146 | 169 | 167 | 186 |
| Expenses | 90 | 99 | 100 | 95 | 103 | 107 | 107 | 102 | 103 | 104 | 114 | 122 | 129 |
| Operating Profit | 31 | 40 | 42 | 44 | 44 | 51 | 54 | 55 | 51 | 42 | 55 | 46 | 56 |
| OPM % | 26% | 29% | 29% | 32% | 30% | 32% | 33% | 35% | 33% | 29% | 33% | 27% | 30% |
| Other Income | 2 | 4 | 9 | 7 | 7 | 6 | 14 | -6 | 7 | 10 | 8 | 9 | 9 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 |
| Profit before tax | 24 | 34 | 40 | 42 | 41 | 48 | 59 | 40 | 49 | 42 | 53 | 43 | 55 |
| Tax % | 26% | 23% | 31% | 24% | 29% | 27% | 28% | 25% | 28% | 21% | 27% | 38% | 26% |
| Net Profit | 18 | 26 | 28 | 32 | 29 | 35 | 42 | 30 | 35 | 33 | 39 | 27 | 40 |
| EPS in Rs | 1.60 | 2.34 | 2.63 | 2.87 | 2.58 | 3.08 | 3.74 | 2.53 | 3.05 | 2.94 | 3.37 | 2.37 | 3.57 |
Last Updated: August 20, 2025, 2:15 pm
Below is a detailed analysis of the quarterly data for Advanced Enzyme Technologies Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 186.00 Cr.. The value appears strong and on an upward trend. It has increased from 167.00 Cr. (Mar 2025) to 186.00 Cr., marking an increase of 19.00 Cr..
- For Expenses, as of Jun 2025, the value is 129.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 122.00 Cr. (Mar 2025) to 129.00 Cr., marking an increase of 7.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 56.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Mar 2025) to 56.00 Cr., marking an increase of 10.00 Cr..
- For OPM %, as of Jun 2025, the value is 30.00%. The value appears strong and on an upward trend. It has increased from 27.00% (Mar 2025) to 30.00%, marking an increase of 3.00%.
- For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 55.00 Cr.. The value appears strong and on an upward trend. It has increased from 43.00 Cr. (Mar 2025) to 55.00 Cr., marking an increase of 12.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 38.00% (Mar 2025) to 26.00%, marking a decrease of 12.00%.
- For Net Profit, as of Jun 2025, the value is 40.00 Cr.. The value appears strong and on an upward trend. It has increased from 27.00 Cr. (Mar 2025) to 40.00 Cr., marking an increase of 13.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 3.57. The value appears strong and on an upward trend. It has increased from 2.37 (Mar 2025) to 3.57, marking an increase of 1.20.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:46 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 239 | 222 | 293 | 329 | 391 | 420 | 444 | 502 | 529 | 541 | 624 | 637 | 668 |
| Expenses | 189 | 131 | 155 | 177 | 226 | 236 | 241 | 269 | 327 | 382 | 418 | 441 | 469 |
| Operating Profit | 50 | 91 | 138 | 152 | 165 | 184 | 203 | 233 | 203 | 158 | 206 | 196 | 200 |
| OPM % | 21% | 41% | 47% | 46% | 42% | 44% | 46% | 46% | 38% | 29% | 33% | 31% | 30% |
| Other Income | 1 | 1 | -3 | 3 | 1 | 5 | 6 | 9 | 6 | 21 | 21 | 33 | 35 |
| Interest | 13 | 9 | 8 | 4 | 9 | 5 | 4 | 3 | 3 | 3 | 4 | 5 | 3 |
| Depreciation | 10 | 9 | 9 | 13 | 18 | 21 | 26 | 29 | 35 | 35 | 35 | 37 | 38 |
| Profit before tax | 28 | 74 | 118 | 137 | 139 | 162 | 179 | 210 | 171 | 140 | 188 | 187 | 194 |
| Tax % | 23% | 31% | 35% | 32% | 33% | 28% | 26% | 28% | 28% | 26% | 27% | 28% | |
| Net Profit | 21 | 51 | 77 | 93 | 94 | 116 | 133 | 151 | 124 | 104 | 137 | 134 | 139 |
| EPS in Rs | 1.85 | 4.60 | 6.97 | 8.20 | 8.07 | 9.95 | 11.58 | 13.06 | 10.70 | 9.45 | 11.92 | 11.72 | 12.25 |
| Dividend Payout % | 6% | 4% | 3% | 5% | 6% | 6% | 5% | 7% | 9% | 11% | 43% | 44% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 142.86% | 50.98% | 20.78% | 1.08% | 23.40% | 14.66% | 13.53% | -17.88% | -16.13% | 31.73% | -2.19% |
| Change in YoY Net Profit Growth (%) | 0.00% | -91.88% | -30.20% | -19.70% | 22.33% | -8.75% | -1.12% | -31.41% | 1.75% | 47.86% | -33.92% |
Advanced Enzyme Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 7% |
| 3 Years: | 6% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 0% |
| 3 Years: | 3% |
| TTM: | -8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 8% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | 10% |
| Last Year: | 10% |
Last Updated: September 4, 2025, 10:20 pm
Balance Sheet
Last Updated: July 25, 2025, 3:40 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves | 145 | 188 | 256 | 442 | 537 | 657 | 817 | 949 | 1,066 | 1,213 | 1,302 | 1,398 |
| Borrowings | 167 | 115 | 101 | 54 | 67 | 35 | 28 | 28 | 35 | 34 | 47 | 39 |
| Other Liabilities | 73 | 92 | 71 | 65 | 102 | 91 | 104 | 150 | 137 | 142 | 150 | 151 |
| Total Liabilities | 406 | 417 | 450 | 583 | 727 | 805 | 971 | 1,149 | 1,260 | 1,411 | 1,521 | 1,611 |
| Fixed Assets | 287 | 287 | 285 | 421 | 491 | 495 | 563 | 604 | 619 | 649 | 650 | 679 |
| CWIP | 2 | 5 | 7 | 8 | 11 | 10 | 10 | 10 | 15 | 22 | 41 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 111 | 124 | 121 | 102 | 360 | 403 | 480 |
| Other Assets | 117 | 125 | 158 | 153 | 226 | 188 | 275 | 414 | 524 | 380 | 427 | 430 |
| Total Assets | 406 | 417 | 450 | 583 | 727 | 805 | 971 | 1,149 | 1,260 | 1,411 | 1,521 | 1,611 |
Below is a detailed analysis of the balance sheet data for Advanced Enzyme Technologies Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 22.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,398.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,302.00 Cr. (Mar 2024) to 1,398.00 Cr., marking an increase of 96.00 Cr..
- For Borrowings, as of Mar 2025, the value is 39.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 47.00 Cr. (Mar 2024) to 39.00 Cr., marking a decrease of 8.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 151.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 150.00 Cr. (Mar 2024) to 151.00 Cr., marking an increase of 1.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,611.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,521.00 Cr. (Mar 2024) to 1,611.00 Cr., marking an increase of 90.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 679.00 Cr.. The value appears strong and on an upward trend. It has increased from 650.00 Cr. (Mar 2024) to 679.00 Cr., marking an increase of 29.00 Cr..
- For CWIP, as of Mar 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Mar 2024) to 22.00 Cr., marking a decrease of 19.00 Cr..
- For Investments, as of Mar 2025, the value is 480.00 Cr.. The value appears strong and on an upward trend. It has increased from 403.00 Cr. (Mar 2024) to 480.00 Cr., marking an increase of 77.00 Cr..
- For Other Assets, as of Mar 2025, the value is 430.00 Cr.. The value appears strong and on an upward trend. It has increased from 427.00 Cr. (Mar 2024) to 430.00 Cr., marking an increase of 3.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,611.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,521.00 Cr. (Mar 2024) to 1,611.00 Cr., marking an increase of 90.00 Cr..
Notably, the Reserves (1,398.00 Cr.) exceed the Borrowings (39.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -117.00 | -24.00 | 37.00 | 98.00 | 98.00 | 149.00 | 175.00 | 205.00 | 168.00 | 124.00 | 159.00 | 157.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 49 | 61 | 52 | 55 | 55 | 51 | 61 | 63 | 61 | 68 | 58 | 66 |
| Inventory Days | 387 | 403 | 358 | 352 | 339 | 363 | 361 | 346 | 402 | 343 | 375 | 378 |
| Days Payable | 81 | 89 | 68 | 57 | 78 | 46 | 43 | 56 | 60 | 67 | 40 | 41 |
| Cash Conversion Cycle | 356 | 374 | 342 | 351 | 315 | 369 | 379 | 353 | 404 | 344 | 393 | 403 |
| Working Capital Days | -54 | -43 | 3 | 76 | 47 | 72 | 90 | 94 | 116 | 109 | 102 | 112 |
| ROCE % | 12% | 25% | 36% | 31% | 25% | 24% | 22% | 22% | 15% | 12% | 15% | 13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund - Regular Plan | 3,979,689 | 0.58 | 130.55 | 3,979,689 | 2025-04-22 15:57:00 | 0% |
| ICICI Prudential ESG Fund | 1,000,321 | 2.55 | 32.82 | 1,000,321 | 2025-04-22 15:57:00 | 0% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 860,609 | 0.89 | 28.23 | 860,609 | 2025-04-22 15:57:00 | 0% |
| ICICI Prudential Value Discovery Fund | 644,400 | 0.06 | 21.14 | 644,400 | 2025-04-22 17:25:43 | 0% |
| HDFC Multi Cap Fund | 507,664 | 0.2 | 16.65 | 507,664 | 2025-04-22 15:57:00 | 0% |
| ICICI Prudential Equity & Debt Fund | 115,918 | 0.02 | 3.8 | 115,918 | 2025-04-22 15:57:00 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 388 | 0.16 | 0.01 | 388 | 2025-04-22 17:25:43 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 11.72 | 11.92 | 9.45 | 10.70 | 13.09 |
| Diluted EPS (Rs.) | 11.71 | 11.92 | 9.45 | 10.68 | 13.07 |
| Cash EPS (Rs.) | 15.24 | 15.40 | 12.42 | 14.20 | 16.10 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 127.00 | 122.61 | 114.84 | 102.00 | 92.25 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 127.00 | 122.61 | 114.84 | 102.00 | 92.25 |
| Revenue From Operations / Share (Rs.) | 56.93 | 55.79 | 48.35 | 47.35 | 44.92 |
| PBDIT / Share (Rs.) | 20.33 | 21.56 | 16.27 | 18.59 | 21.51 |
| PBIT / Share (Rs.) | 17.06 | 18.41 | 13.13 | 15.46 | 18.97 |
| PBT / Share (Rs.) | 16.75 | 16.80 | 12.55 | 15.30 | 18.83 |
| Net Profit / Share (Rs.) | 11.97 | 12.25 | 9.29 | 11.07 | 13.56 |
| NP After MI And SOA / Share (Rs.) | 11.72 | 11.92 | 9.45 | 10.70 | 13.08 |
| PBDIT Margin (%) | 35.71 | 38.64 | 33.64 | 39.26 | 47.89 |
| PBIT Margin (%) | 29.97 | 33.00 | 27.16 | 32.65 | 42.23 |
| PBT Margin (%) | 29.41 | 30.10 | 25.96 | 32.31 | 41.91 |
| Net Profit Margin (%) | 21.03 | 21.95 | 19.21 | 23.38 | 30.18 |
| NP After MI And SOA Margin (%) | 20.58 | 21.36 | 19.53 | 22.58 | 29.13 |
| Return on Networth / Equity (%) | 9.22 | 10.06 | 8.55 | 10.98 | 15.06 |
| Return on Capital Employeed (%) | 12.52 | 14.40 | 10.92 | 14.31 | 19.53 |
| Return On Assets (%) | 8.08 | 8.68 | 7.42 | 9.43 | 12.68 |
| Long Term Debt / Equity (X) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Total Debt / Equity (X) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Asset Turnover Ratio (%) | 0.40 | 0.42 | 0.33 | 0.32 | 0.38 |
| Current Ratio (X) | 9.09 | 7.61 | 9.31 | 10.00 | 7.64 |
| Quick Ratio (X) | 7.47 | 6.22 | 7.71 | 8.00 | 6.25 |
| Inventory Turnover Ratio (X) | 1.06 | 1.14 | 1.23 | 1.30 | 1.32 |
| Dividend Payout Ratio (NP) (%) | 43.49 | 41.94 | 10.58 | 8.41 | 4.58 |
| Dividend Payout Ratio (CP) (%) | 34.01 | 33.17 | 7.94 | 6.50 | 3.83 |
| Earning Retention Ratio (%) | 56.51 | 58.06 | 89.42 | 91.59 | 95.42 |
| Cash Earning Retention Ratio (%) | 65.99 | 66.83 | 92.06 | 93.50 | 96.17 |
| Interest Coverage Ratio (X) | 63.95 | 82.35 | 75.13 | 115.72 | 150.80 |
| Interest Coverage Ratio (Post Tax) (X) | 38.66 | 52.94 | 45.58 | 69.93 | 96.02 |
| Enterprise Value (Cr.) | 3081.99 | 3814.49 | 2529.42 | 2942.98 | 3729.91 |
| EV / Net Operating Revenue (X) | 4.84 | 6.11 | 4.68 | 5.56 | 7.43 |
| EV / EBITDA (X) | 13.55 | 15.82 | 13.91 | 14.16 | 15.52 |
| MarketCap / Net Operating Revenue (X) | 4.90 | 6.23 | 4.79 | 5.96 | 7.68 |
| Retention Ratios (%) | 56.50 | 58.05 | 89.41 | 91.58 | 95.41 |
| Price / BV (X) | 2.20 | 2.93 | 2.10 | 2.90 | 3.97 |
| Price / Net Operating Revenue (X) | 4.90 | 6.23 | 4.79 | 5.96 | 7.68 |
| EarningsYield | 0.04 | 0.03 | 0.04 | 0.03 | 0.03 |
After reviewing the key financial ratios for Advanced Enzyme Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 11.72. This value is within the healthy range. It has decreased from 11.92 (Mar 24) to 11.72, marking a decrease of 0.20.
- For Diluted EPS (Rs.), as of Mar 25, the value is 11.71. This value is within the healthy range. It has decreased from 11.92 (Mar 24) to 11.71, marking a decrease of 0.21.
- For Cash EPS (Rs.), as of Mar 25, the value is 15.24. This value is within the healthy range. It has decreased from 15.40 (Mar 24) to 15.24, marking a decrease of 0.16.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 127.00. It has increased from 122.61 (Mar 24) to 127.00, marking an increase of 4.39.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 127.00. It has increased from 122.61 (Mar 24) to 127.00, marking an increase of 4.39.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 56.93. It has increased from 55.79 (Mar 24) to 56.93, marking an increase of 1.14.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 20.33. This value is within the healthy range. It has decreased from 21.56 (Mar 24) to 20.33, marking a decrease of 1.23.
- For PBIT / Share (Rs.), as of Mar 25, the value is 17.06. This value is within the healthy range. It has decreased from 18.41 (Mar 24) to 17.06, marking a decrease of 1.35.
- For PBT / Share (Rs.), as of Mar 25, the value is 16.75. This value is within the healthy range. It has decreased from 16.80 (Mar 24) to 16.75, marking a decrease of 0.05.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 11.97. This value is within the healthy range. It has decreased from 12.25 (Mar 24) to 11.97, marking a decrease of 0.28.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 11.72. This value is within the healthy range. It has decreased from 11.92 (Mar 24) to 11.72, marking a decrease of 0.20.
- For PBDIT Margin (%), as of Mar 25, the value is 35.71. This value is within the healthy range. It has decreased from 38.64 (Mar 24) to 35.71, marking a decrease of 2.93.
- For PBIT Margin (%), as of Mar 25, the value is 29.97. This value exceeds the healthy maximum of 20. It has decreased from 33.00 (Mar 24) to 29.97, marking a decrease of 3.03.
- For PBT Margin (%), as of Mar 25, the value is 29.41. This value is within the healthy range. It has decreased from 30.10 (Mar 24) to 29.41, marking a decrease of 0.69.
- For Net Profit Margin (%), as of Mar 25, the value is 21.03. This value exceeds the healthy maximum of 10. It has decreased from 21.95 (Mar 24) to 21.03, marking a decrease of 0.92.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 20.58. This value exceeds the healthy maximum of 20. It has decreased from 21.36 (Mar 24) to 20.58, marking a decrease of 0.78.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.22. This value is below the healthy minimum of 15. It has decreased from 10.06 (Mar 24) to 9.22, marking a decrease of 0.84.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.52. This value is within the healthy range. It has decreased from 14.40 (Mar 24) to 12.52, marking a decrease of 1.88.
- For Return On Assets (%), as of Mar 25, the value is 8.08. This value is within the healthy range. It has decreased from 8.68 (Mar 24) to 8.08, marking a decrease of 0.60.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.40. It has decreased from 0.42 (Mar 24) to 0.40, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 9.09. This value exceeds the healthy maximum of 3. It has increased from 7.61 (Mar 24) to 9.09, marking an increase of 1.48.
- For Quick Ratio (X), as of Mar 25, the value is 7.47. This value exceeds the healthy maximum of 2. It has increased from 6.22 (Mar 24) to 7.47, marking an increase of 1.25.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 4. It has decreased from 1.14 (Mar 24) to 1.06, marking a decrease of 0.08.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 43.49. This value is within the healthy range. It has increased from 41.94 (Mar 24) to 43.49, marking an increase of 1.55.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 34.01. This value is within the healthy range. It has increased from 33.17 (Mar 24) to 34.01, marking an increase of 0.84.
- For Earning Retention Ratio (%), as of Mar 25, the value is 56.51. This value is within the healthy range. It has decreased from 58.06 (Mar 24) to 56.51, marking a decrease of 1.55.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 65.99. This value is within the healthy range. It has decreased from 66.83 (Mar 24) to 65.99, marking a decrease of 0.84.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 63.95. This value is within the healthy range. It has decreased from 82.35 (Mar 24) to 63.95, marking a decrease of 18.40.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 38.66. This value is within the healthy range. It has decreased from 52.94 (Mar 24) to 38.66, marking a decrease of 14.28.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,081.99. It has decreased from 3,814.49 (Mar 24) to 3,081.99, marking a decrease of 732.50.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.84. This value exceeds the healthy maximum of 3. It has decreased from 6.11 (Mar 24) to 4.84, marking a decrease of 1.27.
- For EV / EBITDA (X), as of Mar 25, the value is 13.55. This value is within the healthy range. It has decreased from 15.82 (Mar 24) to 13.55, marking a decrease of 2.27.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.90. This value exceeds the healthy maximum of 3. It has decreased from 6.23 (Mar 24) to 4.90, marking a decrease of 1.33.
- For Retention Ratios (%), as of Mar 25, the value is 56.50. This value is within the healthy range. It has decreased from 58.05 (Mar 24) to 56.50, marking a decrease of 1.55.
- For Price / BV (X), as of Mar 25, the value is 2.20. This value is within the healthy range. It has decreased from 2.93 (Mar 24) to 2.20, marking a decrease of 0.73.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.90. This value exceeds the healthy maximum of 3. It has decreased from 6.23 (Mar 24) to 4.90, marking a decrease of 1.33.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Advanced Enzyme Technologies Ltd:
- Net Profit Margin: 21.03%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.52% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.22% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 38.66
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 7.47
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 26.1 (Industry average Stock P/E: 54.46)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 21.03%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A - Wing, Sun Magnetica, 5th Floor, LIC Service Road, Thane Maharashtra 400604 | info@advancedenzymes.com http://www.advancedenzymes.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vasant Rathi | Non Executive Chairman |
| Mr. Mukund Kabra | Whole Time Director |
| Ms. Rasika Rathi | Non Executive Director |
| Dr. Sunny Sharma | Non Executive Director |
| Mr. Pramod Kasat | Independent Director |
| Mrs. Vandana Tilak | Independent Director |
| Ms. Rajshree Patel | Independent Director |
| Mr. Nitin Desmukh | Independent Director |
| Mr. Vinodkumar Jajoo | Independent Director |
FAQ
What is the intrinsic value of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd's intrinsic value (as of 03 November 2025) is 257.10 which is 19.40% lower the current market price of 319.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,572 Cr. market cap, FY2025-2026 high/low of 509/258, reserves of ₹1,398 Cr, and liabilities of 1,611 Cr.
What is the Market Cap of Advanced Enzyme Technologies Ltd?
The Market Cap of Advanced Enzyme Technologies Ltd is 3,572 Cr..
What is the current Stock Price of Advanced Enzyme Technologies Ltd as on 03 November 2025?
The current stock price of Advanced Enzyme Technologies Ltd as on 03 November 2025 is 319.
What is the High / Low of Advanced Enzyme Technologies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Advanced Enzyme Technologies Ltd stocks is 509/258.
What is the Stock P/E of Advanced Enzyme Technologies Ltd?
The Stock P/E of Advanced Enzyme Technologies Ltd is 26.1.
What is the Book Value of Advanced Enzyme Technologies Ltd?
The Book Value of Advanced Enzyme Technologies Ltd is 127.
What is the Dividend Yield of Advanced Enzyme Technologies Ltd?
The Dividend Yield of Advanced Enzyme Technologies Ltd is 1.63 %.
What is the ROCE of Advanced Enzyme Technologies Ltd?
The ROCE of Advanced Enzyme Technologies Ltd is 13.1 %.
What is the ROE of Advanced Enzyme Technologies Ltd?
The ROE of Advanced Enzyme Technologies Ltd is 9.54 %.
What is the Face Value of Advanced Enzyme Technologies Ltd?
The Face Value of Advanced Enzyme Technologies Ltd is 2.00.